SecBot SecBot
8-K ·Filed Jul 10, 2026

NRXS

Neuraxis, INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001493152-26-032769
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Routine preferred stock dividend — no material impact on common equity holders. Monitor upcoming quarterly earnings for operational performance and cash runway updates.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
NRXS ▲ +0.14% at T+60d
NEUTRAL call +0.14% · α vs SPY -2.49% · entry $7.14 → $7.15
Entry = T+0 close
Jul 10, 2026
via day close
T+1d
-3.64%
call -3.64% · α -2.88%
$6.88
settled 4mo ago
T+5d
-5.04%
call -5.04% · α -4.48%
$6.78
settled 3mo ago
T+20d
-0.70%
call -0.70% · α -3.13%
$7.09
settled 3mo ago
T+60d
+0.14%
call +0.14% · α -2.49%
$7.15
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Neuraxis declared a Q2 2026 stock dividend on its Series B Preferred Stock, payable in common stock on July 29, 2026. The dividend will result in the issuance of approximately 80,463 common shares at a reference price of $2.38 per share. This is a routine preferred dividend payment with no material operational or financial impact on common equity holders.

Key Facts

  • Series B Preferred Stock Q2 2026 dividend declared on July 9, 2026
  • Dividend payable July 29, 2026 to holders of record July 21, 2026
  • Approximately 80,463 common shares to be issued as payment
  • Reference price for calculating share count: $2.38 per share
  • No fractional shares; cash-in-lieu for fractional interests

Financial Impact

Approximately 80,463 common shares (~0.1% dilution at sub-$100M market cap) to satisfy Series B preferred dividend; immaterial relative to total equity

dilutionshares outstanding

Risk Factors

  • Preferred dividend payments in stock could signal cash conservation constraints
  • Sustained stock-based dividend payments may increase dilution over time

Market Snapshot

Exchange
NYSE
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-032769
Document: 0001493152-26-032769-index-headers.html0001493152-26-032769
Document: 0001493152-26-032769-index.html0001493152-26-032769
Document: 0001493152-26-032769.txt0001493152-26-032769
14 reports for NRXS
Performance horizon
50% Hit rate @ T+20 2 of 4 directional calls Went positive at some point 3 of 4 best @ T+20▲ +17.12%Aug 4, 2026
Filters
Rows
Reports for NRXS — sortable, filterable
TypeNow
Oct 14, 2026
12d ago
8-K
NEUTRAL ★ 2/10
$7.74awaiting T+20—$7.25 (−6.33%)
Aug 19, 2026
9w ago
8-K
NEUTRAL ★ 2/10
$6.27 $7.61▲ +21.37%▲ +21.37%$7.25 (+15.63%)
Aug 11, 2026
10w ago
Press Release
MIXED ★ 5/10
$6.35 $5.73▼ −9.76%▼ −8.70%$7.25 (+14.17%)
Aug 4, 2026
12w ago
EFFECT
BEARISH ★ 6/10
$7.01 $5.81▲ +17.12%▲ +15.88%$7.25 (−3.42%)
Jul 30, 2026
12w ago
S-3/A
BEARISH ★ 6/10
$6.28 $6.02▲ +4.14%▲ +8.11%$7.25 (−15.45%)
Jul 10, 2026
15w ago
8-K
NEUTRAL ★ 2/10
$7.14 $7.09▼ −0.70%▼ −3.13%$7.25 (+1.54%)
May 12, 2026
23w ago
Press Release
BULLISH ★ 7/10
$8.27 $6.80▼ −17.78%▼ −16.05%$7.25 (−12.33%)
May 5, 2026
24w ago
Press Release
NEUTRAL ★ 1/10
$8.69 $7.01▼ −19.33%▼ −24.29%$7.25 (−16.57%)
Apr 28, 2026
25w ago
DEFA14A
NEUTRAL ★ 4/10
$7.44 $7.29▼ −2.02%▼ −8.06%$7.25 (−2.55%)
Apr 21, 2026
26w ago
8-K
BULLISH ★ 7/10
$7.51 $7.25▼ −3.46%▼ −6.63%$7.25 (−3.46%)
Showing 10 of 14

US Market Status

Market Closed — Opens in 3h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 10, 2026